Nektar Therapeutics

NKTR is in Stage 2 with a corrective reset showing higher highs and higher lows above repaired EMA support. Bullish medium-term bias is reinforced by a Bullish Pivot Point and continuation structure, but short-term timing remains neutral as price pulls back into rising EMAs and the 50 DMA. Execution posture is to stalk and await acceptance at the EMA/50 DMA support zone before engaging on the long side.

• ↑Phase II RESPEG trials demonstrate durable and deepening responses
• ↑Ended Q1 2026 with >$1 B cash, funding Phase III development
• ↓Q1 net loss of $44.9 M far exceeds $10.5 M revenues